Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CYBN
stocks logo

CYBN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
--
--
-1.103
+197.25%
--
--
-1.045
-2.29%
--
--
-0.814
+1.9%
Estimates Revision
Stock Price
Go Down
down Image
-11.59%
In Past 3 Month
Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 44.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 44.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.950
sliders
Low
30.00
Averages
44.00
High
55.00
Current: 5.950
sliders
Low
30.00
Averages
44.00
High
55.00
Guggenheim
Buy
maintain
$39 -> $48
2025-12-03
New
Reason
Guggenheim
Price Target
$39 -> $48
2025-12-03
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Cybin to $48 from $39 and keeps a Buy rating on the shares. Noting that the company's Phase 3 program for CYB003 in adjunctive MDD is advancing as planned, the firm says it expects Cybin to have "a strong 2026 performance."
Canaccord
Buy
downgrade
$70 -> $45
2025-11-20
Reason
Canaccord
Price Target
$70 -> $45
2025-11-20
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Cybin to $45 from $70 and keeps a Buy rating on the shares. The firm updated its model to reflect its recent capital raise of about $175M and paydown of its convertible debt. The company is poised for a catalyst rich 2026 and shares remain significantly undervalued.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$150 -> $55
2025-11-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$150 -> $55
2025-11-14
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cybin to $55 from $150 and keeps a Buy rating on the shares. Strong clinical execution, commercial groundwork, and financial strengthening leave Cybin well-positioned ahead of two major 2026 readouts, the firm says. The increased share count from the recent financing, normalization of expenses in Wainwright's model, and fine-tuning its expected CYB003 launch to 2028 and CYB004 launch to 2029 resulted in a revised price target, Wainwright adds.
Canaccord
Buy
downgrade
$73 -> $70
2025-07-08
Reason
Canaccord
Price Target
$73 -> $70
2025-07-08
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Cybin to $70 from $73 and keeps a Buy rating on the shares. The firm noted they recently reported its F4Q25 results and operating expenses came in close to estimates. The key update were that the company is on track to complete its Phase 2 study for CYB004 (deuterated DMT) for generalized anxiety disorder (GAD) in mid- C2025E; and report Phase 3 data for CYB003 (deuterated psilocin analog) for major depressive disorder (MDD) in C2026E. Canaccord continues to believe Cybin is significantly undervalued ahead of data.
Lucid Capital
NULL
to
Buy
initiated
$106
2025-06-06
Reason
Lucid Capital
Price Target
$106
2025-06-06
initiated
NULL
to
Buy
Reason
Guggenheim
Eddie Hickman
Strong Buy
Initiates
$35
2025-03-13
Reason
Guggenheim
Eddie Hickman
Price Target
$35
2025-03-13
Initiates
Strong Buy
Reason
Guggenheim initiated coverage of Cybin with a Buy rating and $35 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cybin Inc (CYBN.A) is -2.55, compared to its 5-year average forward P/E of -4.00. For a more detailed relative valuation and DCF analysis to assess Cybin Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.00
Current PE
-2.55
Overvalued PE
-1.79
Undervalued PE
-6.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.38
Undervalued EV/EBITDA
-19.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
51.11
Current PS
0.00
Overvalued PS
279.35
Undervalued PS
-177.13
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CYBN News & Events

Events Timeline

(ET)
2025-12-04
11:00:00
Clearmind Doses First Participant with CMND-100 at Hadassah Medical Center
select
2025-11-13 (ET)
2025-11-13
10:49:53
Cybin Announces Q2 EPS of $1.39, Exceeding Consensus Estimate of $1.33
select
2025-09-08 (ET)
2025-09-08
08:08:06
Cybin finishes enrolling participants in CYB004 study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15NASDAQ.COM
HC Wainwright & Co. Continues to Recommend Buy for Cybin (CYBN)

  • Analyst Coverage: HC Wainwright & Co. maintains a Buy recommendation for Cybin (NYSEAM:CYBN), despite a projected average one-year price target of $5.14/share indicating a 13.02% downside from its current price of $5.91/share.

  • Fund Sentiment: There has been a 22.58% increase in the number of funds reporting positions in Cybin, with total institutional shares owned rising by 10.29% to 9,374K shares.

  • Shareholder Activity: Notable changes in shareholder positions include Tang Capital Management maintaining its stake, while Point72 Asset Management and Deep Track Capital significantly reduced their holdings by 29.58% and 53.00%, respectively.

  • Market Outlook: The put/call ratio for CYBN is 0.07, suggesting a bullish sentiment among investors, despite the projected annual revenue being reported as 0MM.

[object Object]
Preview
9.5
11-13Newsfilter
Cybin Announces Financial Results and Key Business Developments for Second Quarter of Fiscal Year 2026

  • Financial Highlights: Cybin Inc. completed a registered direct offering raising US$175 million, resulting in a cash position of US$248 million as of September 30, 2025, and reported a net loss of US$33.7 million for the quarter.

  • Clinical Trials Progress: The company is advancing its Phase 2 study of CYB004 for Generalized Anxiety Disorder (GAD) with topline data expected in Q1 2026, and is progressing through Phase 3 studies of CYB003 for Major Depressive Disorder (MDD).

  • Regulatory Approvals: Cybin received approval to conduct the EMBRACE study in multiple countries, including the U.S. and Australia, as part of its Phase 3 program for CYB003, targeting patients with moderate to severe MDD.

  • Leadership and Strategy: The Board of Directors is searching for a new CEO to guide the company through its growth phase, while Cybin continues to expand its intellectual property portfolio with over 100 granted patents and 250 pending applications.

[object Object]
Preview
1.0
11-12Newsfilter
Cybin to Attend the Jefferies Global Healthcare Conference in London

  • Company Presentation: Cybin Inc. will have its Chief Business Officer, George Tziras, present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025, with a live webcast scheduled for November 17 at 12:30 p.m. GMT.

  • Innovative Mental Healthcare: Cybin is a Phase 3 clinical-stage neuropsychiatry company focused on developing next-generation treatments for mental health conditions, including major depressive disorder and generalized anxiety disorder.

  • Drug Development: The company is advancing its proprietary drugs, including CYB003, a deuterated psilocin analog for major depressive disorder, and CYB004, a deuterated N,N-dimethyltryptamine molecule for generalized anxiety disorder.

  • Global Operations: Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland, aiming to address the significant unmet needs in mental health treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cybin Inc (CYBN) stock price today?

The current price of CYBN is 5.95 USD — it has increased 5.68 % in the last trading day.

arrow icon

What is Cybin Inc (CYBN)'s business?

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

arrow icon

What is the price predicton of CYBN Stock?

Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 44.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cybin Inc (CYBN)'s revenue for the last quarter?

Cybin Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cybin Inc (CYBN)'s earnings per share (EPS) for the last quarter?

Cybin Inc. EPS for the last quarter amounts to -1.39 USD, decreased -33.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cybin Inc (CYBN)'s fundamentals?

The market is revising No Change the revenue expectations for CYBN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.59%.
arrow icon

How many employees does Cybin Inc (CYBN). have?

Cybin Inc (CYBN) has 50 emplpoyees as of December 05 2025.

arrow icon

What is Cybin Inc (CYBN) market cap?

Today CYBN has the market capitalization of 274.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free